The company closed a transformational financing of up to $175 million in Q1 2026, significantly strengthening its balance sheet. The Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer's disease is fully enrolled, with a blinded 6-month interim analysis anticipated in early Q3 2026 and topline data expected in early 2027. Based on the current operating plan, existing cash resources are expected to fund planned operations through 2027, including the completion of the PRECISE-AD trial.
Cyborg Score Rationale
ProMIS has secured substantial funding (up to $175M in early 2026), achieved full enrollment in its pivotal Phase 1b Alzheimer's trial ahead of schedule, and offers a differentiated mechanism targeting toxic oligomers rather than plaque. Near-term interim data catalysts (Q3 2026) and a favorable funding runway support momentum, though clinical-stage risks remain material.
Top Insights
PRECISE-AD Phase 1b trial fully enrolled with blinded interim analysis expected early Q3 2026 and 12-month top-line data in early 2027
Closed $175 million financing in Q1 2026, transforming balance sheet from cash-strapped to well-capitalized
PMN310 selectively targets toxic oligomers while sparing plaque, potentially offering improved efficacy and safety versus competitor approaches
Advancing PMN442 as lead candidate for Parkinson's disease and synucleinopathies, currently in IND-enabling studies
Named Competitors
Lecanemab — Anti-amyloid beta antibody for early Alzheimer's disease
Donanemab — Anti-amyloid beta antibody for early Alzheimer's disease
GLP-1 Receptor Agonists — Emerging class showing neuroprotective effects in neurodegenerative disease
Recent Developments
(May 2026) Reported Q1 2026 financial results with cash of $63.8M following financing close
(January 2026) Entered $175M private placement financing agreement to fund PRECISE-AD trial and key milestones
(December 2025) PRECISE-AD Phase 1b trial exceeded enrollment target and became fully enrolled
(March 2026) Announced FY2025 financial results with PRECISE-AD trial fully enrolled and proceeding ahead of schedule
Open the full interactive ProMIS Neurosciences Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.